Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice

Journal of Clinical Investigation

Volumn 120, Issue 6, 2010, Pages 2016-2029

  Ueda, Kazutaka ^a   Takano, Hiroyuki ^a   Niitsuma, Yuriko ^a   Hasegawa, Hiroshi ^a   Uchiyama, Raita ^a   Oka, Toru ^a   Miyazaki, Masaru ^a   Nakaya, Haruaki ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; SONIC HEDGEHOG PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CAPILLARY; CELL MOTILITY; CONTROLLED STUDY; DRUG MECHANISM; ERYTHROPOIESIS; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANIMALS; APOPTOSIS; BONE MARROW CELLS; CAPILLARIES; CYTOKINES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEDGEHOG PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; UP-REGULATION; VENTRICULAR REMODELING;

EID: 77953223654     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39896     Document Type: Article

References (46)

1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348(20):2007-2018.
2. Rosamond W, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-146. (Pubitemid 43754289)
3. Moon C, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A. 2003;100(20):11612-11617. (Pubitemid 37205984)
4. Ohtsuka M, et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J. 2004;18(7):851-853.
5. Harada M, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med. 2005;11(3):305-311. (Pubitemid 40460559)
6. Silverberg DS, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37(7):1775-1780.
7. Ponikowski P, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49(7):753-762. (Pubitemid 46240705)
8. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44(5):959-966. (Pubitemid 39165127)
9. Bahlmann FH, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921-926. (Pubitemid 38129551)
10. Parsa C, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112(7):999-1007. (Pubitemid 38056315)
11. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18(9):1031-1033. (Pubitemid 39561515)
12. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6(6):484-494. (Pubitemid 40769173)
13. Tada H, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res. 2006;71(3):466-477. (Pubitemid 44107864)
14. Asaumi Y, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation. 2007;115(15):2022-2032. (Pubitemid 46625953)
15. Suzuki N, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002;100(7):2279-2288.
16. Li Y, et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res. 2006;71(4):684-694. (Pubitemid 44848006)
17. Hirose S, et al. Erythropoietin attenuates the development of experimental autoimmune myocarditis. Cardiovasc Drugs Ther. 2007;21(1):17-27. (Pubitemid 46594986)
18. Abbate A, Biondi-Zoccai GG, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol. 2002;193(2):145-153.
19. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev. 2008;13(4):415-423.
20. Pagès G, Pouysségur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene- -a concert of activating factors. Cardiovasc Res. 2005;65(3):564-573. (Pubitemid 40138977)
21. Wang L, et al. The sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem. 2007;282(42):32462-32470. (Pubitemid 350106478)
22. Pola R, et al. The morphogen sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med. 2001;7(6):706-711. (Pubitemid 32588027)
23. Kusano KF, et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med. 2005;11(11):1197-1204.
24. Washington Smoak I, et al. Sonic hedgehog is required for cardiac outflow tract and neural crest cell development. Dev Biol. 2005;283(2):357-372.
25. Lewis PM, et al. Cholesterol modification of sonic hedgehog is required for long-range signaling activity and effective modulation of signaling by Ptc1. Cell. 2001;105(5):599-612.
26. Sohal DS, et al. Temporally regulated and tissue- specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001;89(1):20-25.
27. Suri C, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282(5388):468-471. (Pubitemid 28483672)
28. Asahara T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGFinduced postnatal neovascularization Circ Res. 1998;83(3):233-240. (Pubitemid 28371312)
29. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18(38):5356-5362. (Pubitemid 29462372)
30. Sano M, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444-448. (Pubitemid 46474597)
31. Giordano FJ, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A. 2001;98(10):5780-5785.
32. Lavine KJ, Kovacs A, Ornitz DM. Hedgehog signaling is critical for maintenance of the adult coronary vasculature in mice. J Clin Invest. 2008;118(7):2404-2414. (Pubitemid 351952997)
33. Androutsellis-Theotokis A, et al. Notch signaling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442(7104):823-826. (Pubitemid 44258913)
34. Kasperczyk H, Baumann B, Debatin KM, Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 2009;23(1):21-33.
35. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412(6847):641-647. (Pubitemid 32772276)
36. Funamoto M, et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem. 2000;275(14):10561-10566. (Pubitemid 30202121)
37. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90(22):10705-10709.
38. Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992;257(5073):1138-1141.
39. Leucht C, Stigloher C, Wizenmann A, Klafke R, Folchert A, Bally-Cuif L. MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary. Nat Neurosci. 2008;11(6):641-648. (Pubitemid 351748112)
40. Taipale J, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406(6799):1005-1009.
41. Berman D, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 2002;297(5586):1559-1561. (Pubitemid 34971004)
42. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003;422(6929):313-317. (Pubitemid 36378358)
43. Zhang Y, Pasparakis M, Kollias G, Simons M. Myocyte-dependent regulation of endothelial cell syndecan-4 expression. Role of TNF-alpha. J Biol Chem. 1999;274(8):4786-4790.
44. Zilberberg L, et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem. 2003;278(37):35564-35573. (Pubitemid 37102329)
45. Heineke J, et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest. 2007;117(11):3198-3210. (Pubitemid 350096978)
46. Bendall J, et al. C. Strain-dependent variation in vascular responses to nitric oxide in the isolated murine heart. J Mol Cell Cardiol. 2002;34(10):1325-1333. (Pubitemid 35244410)